OP0064 Discontinuation of Biologic Therapy in Rheumatoid Arthritis (RA): Analysis from the Consortium of Rheumatology Researchers of North America (CORRONA) Database

2013 ◽  
Vol 72 (Suppl 3) ◽  
pp. A71.3-A72 ◽  
Author(s):  
V. Strand ◽  
S. Williams ◽  
P. S. J. Miller ◽  
K. Saunders ◽  
S. Grant ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
North America ◽  
Biologic Therapy

AB1078-HPR Telephone Follow-Up, Standardized To The Initiation of Biologic Therapy of Patients with Rheumatoid Arthritis (RA) in A Specific Unit of Biologic Therapy. Pilot Study

2016 ◽  
Vol 75 (Suppl 2) ◽  
pp. 1300.2-1300 ◽  
Author(s):  
L. Cano-Garcia ◽  
S. Manrique-Arija ◽  
I. Ureña ◽  
N. Mena-Vazquez ◽  
M.C. Ordoñez-Cañizares ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Pilot Study ◽  
Biologic Therapy ◽  
Specific Unit

FRI0293 Characteristics of Patients with Rheumatoid Arthritis Treated with Biologic Therapy as Monotherapy

2014 ◽  
Vol 73 (Suppl 2) ◽  
pp. 490.3-490
Author(s):  
A. Gόmez-Centeno ◽  
O. Martínez ◽  
F. Ballina ◽  
J. Rodriguez ◽  
J. Graña ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Biologic Therapy

scholarly journals Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables

2018 ◽  
Vol Volume 14 ◽  
pp. 2097-2111 ◽  
Author(s):  
Laura Niccoli ◽  
Carlotta Nannini ◽  
Corrado Blandizzi ◽  
Stefania Mantarro ◽  
Marta Mosca ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Biologic Therapy

scholarly journals Biologic therapy of rheumatoid arthritis

2009 ◽  
Vol 137 (3-4) ◽  
pp. 205-210 ◽  
Author(s):  
Nemanja Damjanov ◽  
Jelena Vojinovic
Keyword(s):  
Rheumatoid Arthritis ◽  
Social Impact ◽  
Biologic Therapy ◽  
Joint Damage ◽  
Chronic Arthritis ◽  
Close Monitoring ◽  
Biologic Drugs ◽  
Early Introduction ◽  
Improved Outcomes ◽  
The Individual

Rheumatoid arthritis (RA) and juvenile idiopathic/rheumatoid arthritis (JIA) are chronic, inflammatory, systemic, auto-immune diseases characterized by chronic arthritis leading to progressive joint erosions. The individual functional and social impact of rheumatoid arthritis is of great importance. Disability and joint damage occur rapidly and early in the course of the disease. The remarkably improved outcomes have been achieved initiating biologic therapy with close monitoring of disease progression. Biologic agents are drugs, usually proteins, which can influence chronic immune dysregulation resulting in chronic arthritis. According to the mechanism of action these drugs include: 1) anti-TNF drugs (etanercept, infiximab, adalimumab); 2) IL-1 blocking drugs (anakinra); 3) IL-6 blocking drugs (tocilizumab); 4) agents blocking selective co-stimulation modulation (abatacept); 5) CD 20 blocking drugs (rituximab). Biologics targeting TNF-alpha with methotrexate have revolutionized the treatment of RA, producing significant improvement in clinical, radiographic, and functional outcomes not seen previously. The new concept of rheumatoid arthritis treatment defines early diagnosis, early aggressive therapy with optimal doses of disease modifying antirheumatic drugs (DMARDs) and, if no improvement has been achieved during six months, early introduction of biologic drugs. The three-year experience of biologic therapy in Serbia has shown a positive effect on disease outcome.

Sign in / Sign up

Export Citation Format

Share Document